Advice and guides to help improve your finances!

Aravive Announces Retrospective Analysis of Non-clinical Ovarian Cancer Study

HOUSTONMarch 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that data from a non-clinical ovarian cancer study of AVB-500 and the proprietary GAS6 biomarker assay were highlighted in an oral poster presentation at the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer being held in Honolulu, Hawaii.

The presentation, "Therapeutic AXL/GAS6 inhibition of tumor and tumor microenvironment stromal cells improves response to chemotherapy in ovarian cancer,"  was presented by Katherine Fuh, M.D., Ph.D., and Maggie Mullen, M.D., both from the Center for Reproductive Health SciencesDepartment of Obstetrics and GynecologyWashington University School of Medicine. These data come from a retrospective ex vivo analysis of 40 tumor and serum samples collected pre- and post-neoadjuvant chemotherapy in ovarian cancer patients using Aravive's GAS6 biomarker assay. Additionally, in vitro and in vivo mouse studies were conducted with AVB-500 in combination with chemotherapy.

"This small, non-clinical study continues to support previous literature that highlights the importance of further clinical studies of agents that can specifically and potently inhibit the GAS6/AXL pathway," said Dr. Fuh. "In our pre-clinical work, it appears that AVB-500 has the potential to be an important new medicine for women with ovarian cancer."

Key Study Results:

  • Increased serum and tumor GAS6 levels are associated with chemoresistance and decreased progression free survival (PFS) in patients with high-grade serous ovarian cancer undergoing neoadjuvant treatment.

    • In patients with high tumor GAS6 expression (>80%, n=7) median PFS was 7.7 months compared to 15.2 months in patients with low tumor GAS6 expression (<35%, n=3).
    • In patients with high serum GAS6 levels (>25ng/ml, n=10) median PFS was 9.9 months compared to 20.4 months median PFS in patients with low serum GAS6 levels (<15ng/ml, n=3). 

  • In vitro and in vivo mouse PDX models demonstrated the combination of AVB-500 with chemotherapy decreases tumor and stromal cell viability, tumor burden, and increases DNA damage.

  • The poster will be available online at: https://ir.aravive.com

Aravive is currently enrolling the phase 1b portion of a phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer. The company anticipates reporting interim safety, pharmacodynamic, and pharmacokinetic data for the phase 1b portion in the third quarter of 2019.

 

About Aravive

Aravive, Inc. (Nasdaq: ARAV) is a clinical stage biopharmaceutical company focused on developing innovative therapies that target important survival pathways for cancer. Aravive’s lead candidate, AVB-500, is a novel, high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. 

Aravive has initiated the phase 1b portion of a phase 1b/2 clinical trial of AVB-500 combined with standard of care therapies in patients with platinum-resistant recurrent ovarian cancer, and intends to expand development into additional oncology and fibrotic indications. 

  • For more information, please visit www.aravive.com.

    Aravive Logo.png

    • Source: Aravive, Inc.